Related Experiment Video
Updated: Jun 3, 2026
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Preclinical response of uveal melanomas to the velcrin compound, BAY 2666605
Kristýna Kotýnková1, Sawyer Andersen1, Daniel Denney1
1Broad Institute Cambridge, MA United States.
Abstract:
Velcrin compounds kill cancer cells expressing elevated levels of two cellular proteins, the PDE3A phosphodiesterase and the SLFN12 tRNase, by inducing PDE3A-SLFN12 complex formation. This results in activation of SLFN12, leading to digestion of its specific substrate, tRNA-Leu-TAA, inhibition of protein synthesis, and cell death, a process now called "tomoptosis". We hypothesized that velcrins such as BAY 2666605, a clinical velcrin, could be active against biomarker-positive uveal melanomas. We identified uveal melanoma cell lines expressing elevated levels of the biomarkers, PDE3A and SLFN12, and tested response to velcrin compounds in vitro and in vivo. We show that response correlates mechanistically with decreased levels of tRNA-Leu-TAA and inhibition of nascent protein synthesis and furthermore identify a potential mechanism of resistance.
Insights
Velcrin compounds induce cancer cell death by forming PDE3A-SLFN12 complexes, activating SLFN12 to degrade tRNA and halt protein synthesis. This mechanism, termed tomoptosis, shows potential against biomarker-positive uveal melanomas.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Velcrin compounds target cancer cells expressing elevated PDE3A phosphodiesterase and SLFN12 tRNase.
- This interaction triggers a cascade leading to programmed cell death, termed tomoptosis.
Purpose of the Study:
- To investigate the efficacy of velcrin compounds, specifically BAY 2666605, against uveal melanomas.
- To confirm the mechanistic link between biomarker expression and velcrin response in uveal melanoma models.
Main Methods:
- Identification of uveal melanoma cell lines with high PDE3A and SLFN12 expression.
- In vitro and in vivo testing of velcrin compound efficacy.
- Analysis of tRNA-Leu-TAA levels and nascent protein synthesis inhibition.
Main Results:
- Velcrin compounds demonstrated activity in biomarker-positive uveal melanoma models.
- Response correlated with reduced tRNA-Leu-TAA levels and inhibited protein synthesis.
- A potential mechanism of resistance to velcrin treatment was identified.
Conclusions:
- Velcrins represent a promising therapeutic strategy for uveal melanomas expressing PDE3A and SLFN12.
- The tomoptosis pathway is a key determinant of velcrin efficacy.
- Understanding resistance mechanisms is crucial for optimizing velcrin-based therapies.
